Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE
 | |
| Company type | Subsidiary |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2010, in Waltham, Massachusetts |
| Headquarters | , United States  |
| Products | Varubi |
Number of employees | 286 (2016) |
| Parent | GSK (2019–present) |
| Website | tesarobio |
Tesaro Inc. is a pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
History
Tesaro was founded in 2010.[1] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[2] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[3] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[4] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[5] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[5] On December 3, 2018, GSK announced it would acquire the company for $5.1 billion,[6] and the deal was completed on January 22, 2019.[7]
Products under development
- Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
- Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[8]
- TSR-042
- TSR-022
- Dostarlimab – In February 2023, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.
References
- ^ "Tesaro". FierceBiotech. Retrieved 2017-02-25.
- ^ "TESARO - Quarterly Report". Ir.tesarobio.com. Retrieved 2017-02-25.
- ^ "TESARO - Annual Report". Ir.tesarobio.com. Retrieved 2017-02-25.
- ^ ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA, Street Insider, December 20, 2016, archived from the original on December 21, 2016, retrieved June 8, 2017
{{citation}}: CS1 maint: bot: original URL status unknown (link) - ^ a b D. Rockoff, Jonathan; Cimilluca, Dana (May 31, 2017). "Tesaro Explores Sale". Wall Street Journal. New York City, New York. Retrieved June 1, 2017.
- ^ "GSK slides after buying cancer firm Tesaro for hefty $5.1 billion". 3 December 2018. Archived from the original on December 4, 2018 – via uk.reuters.com.
- ^ "GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company". 22 January 2019.
- ^ "2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial". ESMO. Retrieved 2017-02-25.
External links
- Official website
- Historical business data for Tesaro:
- SEC filings
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
